Alexza Pharmaceuticals (ALXA)
|
4.24
+0.04 (+0.95%)
|
|
|
|
ALXA additional information
Market Data powered by QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Filings and Fundamentals by Morningstar, Insiders by Vickers (USA) and SEDI(CDN), analyst ratings by Zacks.
ALXA Profile
•
Exchange
NASDAQ
•
Held by these Mutual Funds
T. Rowe Price New Horizons
Wasatch Small Cap Growth
T. Rowe Price Health Sciences
iShares Nasdaq Biotechnology
Principal SmallCap Growth R2
iShares Russell 2000 Growth Index
Vanguard Extended Market Idx
DFA US Micro Cap I
Fidelity Select Biotechnology
CREF Social Choice
Wasatch Small Cap Growth
T. Rowe Price Health Sciences
iShares Nasdaq Biotechnology
Principal SmallCap Growth R2
iShares Russell 2000 Growth Index
Vanguard Extended Market Idx
DFA US Micro Cap I
Fidelity Select Biotechnology
CREF Social Choice
•
Competitors
•
Executives
Mr. Thomas B. King
Chief Exec. Officer
Pres Director and Chairman of Fin. Committee
Mr. Mark K. Oki CPA
Chief Financial Officer
Principal Accounting Officer and Sr. VP of Fin.
Mr. Michael J. Simms
Sr. VP of Operations & Manufacturing
Dr. James V. Cassella Ph.D.
Chief Scientific Officer and Exec. VP of R&D
Mr. Darl Moreland
Sr. VP of Quality
Chief Exec. Officer
Pres Director and Chairman of Fin. Committee
Mr. Mark K. Oki CPA
Chief Financial Officer
Principal Accounting Officer and Sr. VP of Fin.
Mr. Michael J. Simms
Sr. VP of Operations & Manufacturing
Dr. James V. Cassella Ph.D.
Chief Scientific Officer and Exec. VP of R&D
Mr. Darl Moreland
Sr. VP of Quality
•
Employee Count
44
Special Offers
Competitors
ALXA earnings
Date
Actual
Expected
Prev Yr Qtr
5/10/2012
-0.04
-0.08
-0.14
3/12/2012
-0.13
-0.12
0.42
11/7/2011
-0.19
-0.14
-0.16
